Biotech BP Architect

3. Disclosure level

public / low disclosure

selective disclosure

full confidential discussion-ready disclosure

4. Company type

single-asset therapeutics

platform therapeutics

diagnostics

tools / enabling technology

cell therapy / gene therapy

synthetic biology / other biotech model

5. Stage

idea / formation

discovery

preclinical

IND-enabling

clinical

6. Raise objective

get first meeting

move from first meeting to diligence

support full diligence

support partnership discussion

If audience or disclosure level is missing, recommend a version split before writing the full BP.

Version gate

This distinction is mandatory.

Non-confidential deck

Goal: earn the next meeting without unnecessary disclosure.

Usually include: 1. Title / company one-liner 2. Executive summary / investment highlights 3. Unmet need 4. Why current approaches fail 5. Company thesis / platform or asset advantage 6. Lead program or strongest proof point 7. Pipeline overview 8. Team 9. Milestones 10. Financing ask and use of proceeds

Do not include:

unpublished technical know-how

detailed protocols

proprietary screening logic

manufacturing trade secrets

non-public partner, investor, customer, or licensing details

unnecessary personal, patient-level, or traceable technical details

Confidential deck

Goal: support serious diligence.

Usually include: 1. Cover page 2. Confidentiality statement page 3. Executive summary 4. Company overview 5. Disease / unmet need 6. Scientific rationale or mechanism 7. Platform or discovery engine 8. Lead program deep dive 9. Supporting data and differentiation 10. Development plan, regulatory path, and milestones 11. Pipeline overview 12. IP / licensing / rights position 13. Team and advisors 14. Financing ask, use of proceeds, and value-inflection milestones 15. Appendix if needed

Include only what the user is authorized to disclose. Even in confidential form, avoid unnecessary personal or patient-level detail.

Confidentiality page

For confidential decks, include one standalone page with both Chinese and English text.

Chinese: 本材料包含[公司名称]的保密信息，仅供经授权的接收方为投资评估或合作评估之目的内部使用。未经[公司名称]事先书面同意，任何人不得全部或部分复制、披露、转载、分发或用于其他目的。本材料所载信息可能持续更新，不构成任何承诺或陈述。

English: This presentation contains confidential information of [Company Name]. It is provided solely to authorized recipients for internal evaluation in connection with a potential investment or business collaboration. No part of this presentation may be copied, disclosed, reproduced, distributed, or used for any other purpose without the prior written consent of [Company Name]. The information herein is subject to update and does not constitute a binding representation or commitment.

This language is drafting support only and not legal advice.

Core BP logic

A biotech BP should answer, in order: 1. What important problem exists? 2. Why do current approaches fall short? 3. What scientific or technical insight changes the odds? 4. Why can this company execute? 5. What evidence already reduces the main risk? 6. What must be proven next? 7. Why is this worth funding now?

Workflow

1. Write the core thesis in one sentence: This company matters because ________.

2. Identify the dominant story:

lead asset with near-term proof

platform already producing credible programs

enabling technology with commercial leverage

clinically de-risked asset with execution upside

hard-to-access biology made tractable by a specific method

3. Find the strongest anchor:

compelling efficacy data

differentiated mechanism

privileged delivery or tissue access

faster regulatory path

unique platform output

founder or operator credibility

public partnership or validation

4. Build the narrative spine:

problem

why current options fail

why this approach can do better

evidence it is more than a concept

path to next value-inflection point

why this team can get there

why invest now

5. Choose slide order by company type rather than forcing one template.

6. Translate each science claim into investor meaning.

7. Flag missing pieces, especially:

unclear indication choice

weak differentiation

weak translational bridge

unclear regulatory path

missing CMC or manufacturability discussion when central

weak IP or rights explanation

no milestone-based use of funds

no explanation of what this round will prove

Output format

Default output should include:

recommended deck version

core thesis sentence

audience and disclosure recommendation

recommended slide order

page-by-page logic, including:

- page title - what question it answers - key claim - evidence to show - what not to include

missing evidence or weak logic

rewrite suggestions

open questions founders must answer before sending

Style rules

use precise language, not slogans

prefer short declarative titles

state unknowns clearly

label early claims honestly

simplify science without hiding risk

tie financing ask to milestones

keep team slides concise unless team quality is central to de-risking

treat reference materials as pattern sources, not copy sources

do not turn assumptions into facts

do not make animal, in vitro, internal, or proposed findings sound like clinical proof

Quality check

Before finalizing, verify:

source ownership / authorization / public status is clear when relevant

audience is clear

confidential vs non-confidential choice is clear

confidential decks include a standalone bilingual confidentiality page

one thesis dominates the deck

the strongest proof point appears early

science slides explain why they matter to an investor

milestones are concrete

financing ask maps to milestones

risks are reduced, not hidden

hypotheses and established facts are separated

no unnecessary sensitive, personal, patient-level, or traceable technical detail appears

no non-public third-party detail appears